MAGEA4 Antibody

Code CSB-PA013330GA01HU
Size $600
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
Cancer/testis antigen 1.4 antibody; CT1.4 antibody; MAGA4_HUMAN antibody; MAGE 4 antibody; MAGE 4 antigen antibody; MAGE 41 antibody; MAGE 41 antigen antibody; MAGE 4A antibody; MAGE 4B antibody; MAGE X2 antibody; MAGE X2 antigen antibody; MAGE-4 antigen antibody; MAGE-41 antigen antibody; MAGE-X2 antigen antibody; MAGE4 antibody; MAGE41 antibody; MAGE4A antibody; MAGE4B antibody; MAGEA 4 antibody; MAGEA4 antibody; Melanoma antigen family A 4 antibody; Melanoma associated antigen 4 antibody; Melanoma-associated antigen 4 antibody; MGC21336 antibody
Raised in
Species Reactivity
Human MAGEA4
Immunogen Species
Homo sapiens (Human)
Purification Method
Antigen Affinity Purified
It differs from different batches. Please contact us to confirm it.
PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
Tested Applications
Troubleshooting and FAQs
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Regulates cell proliferation through the inhibition of cell cycle arrest at the G1 phase. Also negatively regulates p53-mediated apoptosis.
Gene References into Functions
  1. MAGEA4 was positively correlated with TWIST1, and its knockdown inhibited EMT in TE3 cells. PMID: 28653599
  2. Because of the significant correlation of MAGEA4 and indices of poor prognosis, the role of this CTA may be confirmed in Esophageal squamous cell carcinoma (ESCC) aggressiveness and metastasis. Therefore, MAGEA4 may be a promising therapeutic candidate for suppressing ESCC aggressiveness PMID: 30197348
  3. Study shows that whereas MAGEA4 expression by itself may be indicative of a poor prognosis in primary lung cancer, its prognostic value depends entirely on its subcellular localization and on the p53 status. The accumulation of nuclear MAGEA4 expression without p53 expression is significantly associated with poor survival, implying that MAGEA4 inhibits apoptosis and increases tumorigenesis. PMID: 29901069
  4. MAGE-A4 depletion from MAGE-A4-expressing cancer cells destabilizes RAD18. PMID: 27377895
  5. Our results support...the potential utility of MAGEA4 as an ancillary diagnostic marker for synovial sarcoma PMID: 28744588
  6. some autoantibodies, such as anti-MAGEA4, anti-CTAG1 or anti-TP53 and their combinations could possibly contribute to the development of cancer early detection tests (not necessarily restricted to gastric cancer) when being combined with other markers. PMID: 27140836
  7. Anti-MAGEA4 exhibited the highest sensitivity for detecting early stage colorectal cancer (CRC) and advanced adenoma. PMID: 26909861
  8. High MAGE-A4 expression is associated with Lung Cancer. PMID: 27793776
  9. Results found concomitant overexpression of MAGEA4 and TWIST1 in esophageal squamous cell carcinoma (ESCC). Also, it showed a correlation between MAGEA4 and TWIST1 expression, which was found as indirect binding of TWIST1 to the E-boxes in the MAGEA4 promoter revealing transcriptional upregulation of MAGEA4 by TWIST1. PMID: 27533647
  10. Results support the potential utility of NY-ESO-1, PRAME, and MAGEA4 as targets for immunotherapy and as ancillary prognostic parameters in synovial sarcomas. PMID: 27993576
  11. CTAs (MAGE-A4, NY-ESO-1, MAGE-A10) were more likely expressed in patients with squamous cell carcinoma of the lung and when CTAs combined with CD133, they can be better prognostic factors. PMID: 26191258
  12. HLA class I loss in smokers or patients with the MAGE-A4 gene was a prognostic factors in non-small cell lung cancer . PMID: 23124547
  13. Expression of MAGE-A4 may make immunotherapeutic intervention possible in selected patients with thyroid cancer. PMID: 24238058
  14. Detection of MAGE-4 transcripts in blood may help to predict the prognosis and monitoring of the response of HCV-infected hepatocellular carcinoma patients to therapy PMID: 22653756
  15. Mage-A4 expression and serum identification is and potential therapeutic target in estrogen receptor negative breast cancer. PMID: 23172894
  16. MAGEA4 promotes growth by preventing cell cycle arrest and by inhibiting apoptosis mediated by the p53 transcriptional targets. PMID: 22842486
  17. High MAGE-4 gene expression is associated with metastases in hepatitis C virus patients complicated by hepatocellular carcinoma. PMID: 21452042
  18. MAGE-A4 is identified as a specific biomarker of esophageal squamous cell carcinoma with a possible oncogenic role contributing to tumor progression. PMID: 21613820
  19. novel HLA-A2-restricted T cell epitope derived from MAGE-4 was identified PMID: 21815906
  20. High MAGE-A4 gene expression is associated with head and neck squamous cell carcinoma PMID: 20715104
  21. Report immunohistochemical expression of MAGE-A4 in renal oncocytoma and chromophobe renal cell carcinoma. PMID: 20591578
  22. positive expression in patients with non-small cell lung cancer is associated with poorer overall survival PMID: 19545928
  23. MAGE-4 protein may have a role in development of hepatocellular carcinogenesis in cirrhotic patients PMID: 11985796
  24. MAGE-A4 expression in bladder transitional cell carcinoma. PMID: 12209610
  25. strong MAGE-A4 expression and to a lesser degree NY-ESO-1 expression is characteristic of the vast majority of uterine carcinosarcomas and a major subset of papillary serous carcinomas PMID: 12209997
  26. MAGE-A4 binds to gankyrin and suppresses its oncogenic activity. PMID: 12525503
  27. a cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis PMID: 14739298
  28. MAGE-A4(143-151) and SAGE(715-723) are HLA-A2402-restricted CTL epitopes PMID: 16061876
  29. Expression may represent potential targets for cancer immunotherapy in patients with non small cell lung carcinoma. PMID: 16596224
  30. Expressed in a large part of epithelial skin tumors with predominantly scattered immunoexpression pattern in organ-transplant recipients. PMID: 17214847
  31. Its expression is significantly associated with prognostic factors in poor outcome of the non-small cell lung cancer. PMID: 18982744
  32. Overexpression of MAGE-A4 is associated with bladder cancer. PMID: 19533752

Show More

Hide All

Tissue Specificity
Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes and placenta.
Database Links

HGNC: 6802

OMIM: 300175

KEGG: hsa:4103

STRING: 9606.ENSP00000276344

UniGene: Hs.37107

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details


II. Contact details


III. Ship To


IV. Bill To